APA 6th Edition Kovak-Mufić, A., Karlović, D., Martinac, M., Marčinko, D., Letinić, K. i Vidrih, B. (2007). Metabolic side-effects of novel antipsychotic drugs. Biochemia Medica, 17 (2), 178-187. Preuzeto s https://hrcak.srce.hr/18132
MLA 8th Edition Kovak-Mufić, Ana, et al. "Metabolic side-effects of novel antipsychotic drugs." Biochemia Medica, vol. 17, br. 2, 2007, str. 178-187. https://hrcak.srce.hr/18132. Citirano 26.01.2021.
Chicago 17th Edition Kovak-Mufić, Ana, Dalibor Karlović, Marko Martinac, Darko Marčinko, Katica Letinić i Branka Vidrih. "Metabolic side-effects of novel antipsychotic drugs." Biochemia Medica 17, br. 2 (2007): 178-187. https://hrcak.srce.hr/18132
Harvard Kovak-Mufić, A., et al. (2007). 'Metabolic side-effects of novel antipsychotic drugs', Biochemia Medica, 17(2), str. 178-187. Preuzeto s: https://hrcak.srce.hr/18132 (Datum pristupa: 26.01.2021.)
Vancouver Kovak-Mufić A, Karlović D, Martinac M, Marčinko D, Letinić K, Vidrih B. Metabolic side-effects of novel antipsychotic drugs. Biochemia Medica [Internet]. 2007 [pristupljeno 26.01.2021.];17(2):178-187. Dostupno na: https://hrcak.srce.hr/18132
IEEE A. Kovak-Mufić, D. Karlović, M. Martinac, D. Marčinko, K. Letinić i B. Vidrih, "Metabolic side-effects of novel antipsychotic drugs", Biochemia Medica, vol.17, br. 2, str. 178-187, 2007. [Online]. Dostupno na: https://hrcak.srce.hr/18132. [Citirano: 26.01.2021.]
APA 6th Edition Kovak-Mufić, A., Karlović, D., Martinac, M., Marčinko, D., Letinić, K. i Vidrih, B. (2007). Metaboličke nuspojave novijih antipsihotika. Biochemia Medica, 17 (2), 178-187. Preuzeto s https://hrcak.srce.hr/18132
MLA 8th Edition Kovak-Mufić, Ana, et al. "Metaboličke nuspojave novijih antipsihotika." Biochemia Medica, vol. 17, br. 2, 2007, str. 178-187. https://hrcak.srce.hr/18132. Citirano 26.01.2021.
Chicago 17th Edition Kovak-Mufić, Ana, Dalibor Karlović, Marko Martinac, Darko Marčinko, Katica Letinić i Branka Vidrih. "Metaboličke nuspojave novijih antipsihotika." Biochemia Medica 17, br. 2 (2007): 178-187. https://hrcak.srce.hr/18132
Harvard Kovak-Mufić, A., et al. (2007). 'Metaboličke nuspojave novijih antipsihotika', Biochemia Medica, 17(2), str. 178-187. Preuzeto s: https://hrcak.srce.hr/18132 (Datum pristupa: 26.01.2021.)
Vancouver Kovak-Mufić A, Karlović D, Martinac M, Marčinko D, Letinić K, Vidrih B. Metaboličke nuspojave novijih antipsihotika. Biochemia Medica [Internet]. 2007 [pristupljeno 26.01.2021.];17(2):178-187. Dostupno na: https://hrcak.srce.hr/18132
IEEE A. Kovak-Mufić, D. Karlović, M. Martinac, D. Marčinko, K. Letinić i B. Vidrih, "Metaboličke nuspojave novijih antipsihotika", Biochemia Medica, vol.17, br. 2, str. 178-187, 2007. [Online]. Dostupno na: https://hrcak.srce.hr/18132. [Citirano: 26.01.2021.]
Sažetak First descriptions of metabolic side-effects of antipsychotic drugs date back to the 1950s when these drugs were introduced. In the meantime, metabolic side-effects have been shown to occur not only during therapy including conventional antipsychotics like chlorpromazine. Presently, similar problems are encountered with application of the novel, so-called atypical antipsychotics. Introduction of atypical antipsychotics in therapy has substantially promoted the treatment of patients with schizophrenia and other psychotic disorders. Major advantage of these drugs in comparison to conventional antipsychotics is lower frequency of extra pyramidal side-effects and hyperprolactinemia, and generally better tolerance. Still, some atipical antipsychotics are associated to body weight gain, occurrence of diabetes, and elevated cholesterol and triglyceride concentrations.
This review addresses differences in effect of certain atypical antipsychotics on glucose and insulin homeostasis and lipid metabolism, as well as the question of the rational method of applying antipsychotics that are accompanied by metabolic side-effects. For the first time in Croatia, this article provides recommendations for routine clinical practice, i.e. on the monitoring of metabolic status of patients treated by novel antipsychotics.